Stock 300683 WUHAN HITECK BIOLOGICAL PHARMA CO.,LTD
Add to a list
To use this feature you must be a member
Log inSign up

Financials Wuhan Hiteck Biological Pharma Co.,Ltd

Equities

300683

CNE1000034C5

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
23.82 CNY +1.49% Intraday chart for Wuhan Hiteck Biological Pharma Co.,Ltd +9.42% -34.03%
Apr. 21 Wuhan Hiteck Biological Pharma Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
2023 Wuhan Hiteck Biological Pharma Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 2,816 3,110 4,225 7,273 4,322 4,727
Enterprise Value (EV) 1 1,553 1,935 3,232 6,173 3,369 3,704
P/E ratio 29.9 x 49.3 x -170 x 229 x -322 x -38.8 x
Yield 0.73% 0.53% - - - -
Capitalization / Revenue 4.77 x 5.01 x 8.06 x 11.8 x 6.28 x 7.85 x
EV / Revenue 2.63 x 3.12 x 6.17 x 10 x 4.89 x 6.15 x
EV / EBITDA 12.1 x 26.5 x -473 x 285 x 201 x -98.4 x
EV / FCF 6.43 x 2.3 x -19.5 x -14.3 x -27.6 x -45.5 x
FCF Yield 15.6% 43.4% -5.14% -6.98% -3.62% -2.2%
Price to Book 1.66 x 1.77 x 2.47 x 3.13 x 1.87 x 2.07 x
Nbr of stocks (in thousands) 103,355 103,355 103,355 122,104 122,104 130,894
Reference price 2 27.25 30.09 40.88 59.56 35.40 36.11
Announcement Date 4/19/19 4/27/20 4/22/21 4/22/22 4/24/23 4/21/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 590.9 620.2 524.1 614.7 688.6 602.3
EBITDA 1 128.1 73.05 -6.832 21.69 16.74 -37.65
EBIT 1 114.4 50.14 -35.25 -13.2 -33.66 -106.3
Operating Margin 19.36% 8.09% -6.73% -2.15% -4.89% -17.66%
Earnings before Tax (EBT) 1 105.1 72.61 -37.37 20.46 -7.824 -152
Net income 1 94.14 63.04 -25.03 27.65 -14.03 -120.8
Net margin 15.93% 10.16% -4.77% 4.5% -2.04% -20.06%
EPS 2 0.9100 0.6100 -0.2400 0.2600 -0.1100 -0.9300
Free Cash Flow 1 241.6 839.4 -166 -431 -122.1 -81.37
FCF margin 40.88% 135.35% -31.67% -70.11% -17.73% -13.51%
FCF Conversion (EBITDA) 188.59% 1,149.03% - - - -
FCF Conversion (Net income) 256.62% 1,331.66% - - - -
Dividend per Share 2 0.2000 0.1600 - - - -
Announcement Date 4/19/19 4/27/20 4/22/21 4/22/22 4/24/23 4/21/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 1,264 1,175 993 1,100 954 1,023
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 242 839 -166 -431 -122 -81.4
ROE (net income / shareholders' equity) 5.46% 3.53% -1.47% 1.48% -0.34% -5.31%
ROA (Net income/ Total Assets) 3.52% 1.45% -1.01% -0.34% -0.78% -2.34%
Assets 1 2,675 4,350 2,478 -8,187 1,802 5,161
Book Value Per Share 2 16.40 17.00 16.50 19.00 18.90 17.50
Cash Flow per Share 2 2.970 6.730 4.460 1.510 6.130 3.590
Capex 1 38.7 116 114 247 174 167
Capex / Sales 6.54% 18.73% 21.68% 40.2% 25.26% 27.8%
Announcement Date 4/19/19 4/27/20 4/22/21 4/22/22 4/24/23 4/21/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
WUHAN HITECK BIOLOGICAL PHARMA CO.,LTD Stock Wuhan Hiteck Biological Pharma Co.,Ltd
-34.03% 430M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 300683 Stock
  4. Financials Wuhan Hiteck Biological Pharma Co.,Ltd